WallStSmart

Armata Pharmaceuticals Inc (ARMP)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Armata Pharmaceuticals Inc generates 601% more annual revenue ($5.20M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. ARMP earns a higher WallStSmart Score of 28/100 (F).

ARMP

Avoid

28

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 6.7Quality: 5.0
Piotroski: 4/9Altman Z: -15.79

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ARMPUndervalued (+79.8%)

Margin of Safety

+79.8%

Fair Value

$39.70

Current Price

$7.50

$32.20 discount

UndervaluedFair: $39.70Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ARMP2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
60.7%10/10

Revenue surging 60.7% year-over-year

Debt/EquityHealth
-1.2010/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

ARMP4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$290.75M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-3439.0%2/10

ROE of -3439.0% — below average capital efficiency

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ARMP

The strongest argument for ARMP centers on Revenue Growth, Debt/Equity. Revenue growth of 60.7% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : ARMP

The primary concerns for ARMP are EPS Growth, Market Cap, Profit Margin.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

ARMP profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

ARMP is growing revenue faster at 60.7% — sustainability is the question.

ARMP generates stronger free cash flow (-6M), providing more financial flexibility.

Bottom Line

ARMP scores higher overall (28/100 vs 24/100) and 60.7% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Armata Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of specific bacteriophage therapies for the treatment of antibiotic-resistant infections worldwide. The company is headquartered in Marina del Rey, California.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?